Selectively targeting nuclear LSD1 phosphorylated at serine 111 (nLSD1p) might also be a plausible therapeutic approach to tackle the safety issue.510 Similar to most other anti-cancer agents targeting immuno-epigenetic modifiers, LSD1 inhibitors are combined with PD-1/PD-L1 blockade in phase I/II trials with promising preliminary results.511. This evidence concerns the gene CD274 and cancer.